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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
secukinumab is effective in improving physical function in patients with active psoriatic arthritis.
Study Design: Systematic review of three randomized controlled trials (RCTs) published
between 2016 and 2017. All studies were published in the English language.
Data Sources: Three randomized controlled trials (RCTs) published in peer-reviewed journals
comparing the efficacy of secukinumab as an injectable medication for improving physical
function in patients with active psoriatic arthritis. All studies were found using PubMed and Alt
HealthWatch.
Outcomes Measured: In all three studies, improvement in physical function in patients with
active psoriatic arthritis was measured using the Health Assessment Questionnaire Disability
Index (HAQ-DI).
Results: All three studies demonstrated improvement in physical function in patients with active
PsA with the use of secukinumab versus the control group. Kavanaugh et al. (Arthritis Care Res
(2151464X). 2017;69(3):347-355. doi: 10.1002/acr.23111.) reported a mean change from
baseline of approximately -0.4 in both treatment groups (150 mg and 75 mg) and a mean change
from baseline of -0.17 in the comparison placebo group. Strand et al. (Ann Rheum Dis.
2017;76(1):203-207. doi: 10.1136/annrheumdis-2015-209055 [doi]) reported a mean change
from baseline of -0.40 in those receiving 150 mg, -0.41 in those receiving 75 mg and -0.17 in
those receiving a placebo. McInnes et al. (Rheumatology (Oxford). 2017;56(11):1993-2003. doi:
10.1093/rheumatology/kex301 [doi]) reported a mean change from baseline of -0.48 in the group
receiving 150 mg and -0.32 in the group receiving 0.75 mg compared to -0.31 in the placebo
group.
Conclusions: According to all three studies, secukinumab was found to be effective in
improving physical function in patients with active psoriatic arthritis. Further studies are
recommended.
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Introduction
Psoriatic arthritis (PsA) is a chronic, inflammatory disease of the joints where the
immune system creates inflammation leading to pain, swelling, fatigue and stiffness in the joints.
Psoriasis is also an immune mediated disease which causes scaly red patches to appear on a
patient’s skin. PsA most often starts 10 years after the initial psoriasis diagnosis and usually
appears between the ages of 30 and 50.1 PsA can develop without the presence of psoriasis. PsA
can be mild or oligoarticular which refers to four or less joints being affected, or can progress to
a more severe polyarticular form affecting more than four joints.
The incidence of PsA is approximately 6 per 100,000 per year and the prevalence is
approximately 1 to 2 per 1000 in the general population.2 PsA is seen in about 30% of people
with psoriasis.1 An exact number for the total healthcare cost of PsA has not been identified;
however it is estimated that psoriasis costs the United States up to $135 billion per year.3 In the
U.S., the direct annual health care costs for PsA are estimated to be as high as $1.9 billion.4
There is no exact estimate available for PsA health care visits within the past few years;
however, in regards to psoriasis, it has been reported that over 3 million health care visits occur
every year.5
The exact cause of PsA is unknown; however research suggests that both genetics and
environmental triggers play a role in the autoimmune process where the body mistakenly attacks
healthy tissue leading to inflammation, and subsequent joint stiffness, swelling and pain.1
Different triggers including stress, medication and infection can cause an exacerbation or flare up
of PsA. Symptoms of PsA include fatigue, joint pain, stiffness, swelling and tenderness, reduced
range of motion, swollen fingers, toenail and finger nail changes. Dactylitis, which refers to the
swelling of an entire finger is a unique symptom of PsA. Enthesitis is also unique to PsA and
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refers to inflammation of the site where ligaments or tendons insert into bones. The most
common sites include the Achilles tendon, bottom of the foot, ribs, spine and pelvis. There is no
definitive diagnostic test for PsA, therefore a process of elimination, as well as clinical
observations are used to diagnosis this condition. Accordingly, psoriatic plaques and nail
changes are suggestive of PsA and can help differentiate it from rheumatoid arthritis.1
There is no cure for PsA, however there are many treatments used to slow disease
progression, decrease pain and prevent permanent joint damage. It is imperative that patients
with PsA work with a rheumatologist to create a treatment plan in order to reduce inflammation
and prevent joint damage that could be caused by delaying treatment.1 Anti-inflammatory drugs
such as non-steroidal inflammatory drugs (NSAIDs) including ibuprofen and aspirin are
commonly used to treat pain and inflammation.6 Disease-modifying antirheumatic drugs
(DMARDs) such as methotrexate and sulfasalazine can be used to treat symptoms of PsA, in
addition to preventing joint destruction.6 Corticosteroids can also be used for an acute
exacerbation but are not recommended for long term care.6 Biologic drugs are given
intramuscularly or intravenously and work by targeting specific parts of a patient’s immune
system.6 They are used for many autoimmune diseases including psoriasis and PsA, and are
usually initiated when a patient does not respond to other treatments. Instead of targeting the
entire patient’s immune system, biologics only target specific parts.6 Biologics can block T-cells,
specifically tumor necrosis factor-alpha, interleukin 17-A or interleukin-23, all of which are
involved in the development of psoriasis and PsA.6 Secukinumab is a biologic drug, a
monoclonal antibody specifically, that binds to and inhibits interleukin 17 (IL-17), which is a
cytokine that is involved with the inflammatory immune responses in the body.6 By decreasing
the levels of IL-17, secukinumab can improve symptoms of PsA by altering the inflammatory
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cycle.6 This paper evaluates three randomized controlled trials (RCTs) comparing the efficacy of
secukinumab as an injectable medication in improving physical function in patients with active
PsA.
Objective
The objective of this selective EBM review is to determine whether or not secukinumab
is effective in improving physical function in patients with active psoriatic arthritis.
Methods
This systematic review uses three randomized controlled trials (RCTs). The selected
populations include patients over the age of 18 with a diagnosis of active psoriatic arthritis. The
intervention in these studies was treatment with secukinumab. The treatment group was
compared to an experimental group receiving a placebo. The outcome measured was the
improvement of patients’ physical function based on the Health Assessment Questionnaire
Disability Index (HAQ-DI).
The articles were found using the keywords “secukinumab” and “psoriatic arthritis”. The
three articles were published in peer-reviewed journals, no earlier than 2008 and in the English
language. All the articles were researched using PubMed and Alt HealthWatch. Articles selected
displayed relevance to the clinical question and were required to study outcomes that were
patient oriented evidence that matters (POEM). Studies with published systematic reviews were
excluded, as well as studies with subjects under the age of 18. Statistics reported included mean
change from baseline and p values from earlier phases of the studies. Table 1 includes inclusion
and exclusion criteria specific to each of the studies in this systematic review.
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Table 1. Demographics and characteristics of included studies
Study
Type #
Age
Inclusion
Exclusion Criteria W/D
Pts (yrs) Criteria
Kavanaugh
, 20167

RCT

606

> 18
years

Patients 18
years or
older with
moderate to
severe
active PsA

McInnes,
20178

RCT

397

> 18
years

Adults > 18
years old
with active
PsA

Strand,
20179

RCT

606

> 18
years

Adults > 18
years of age
fulfilling
criteria for
active PsA

Previous therapy
with biologics
other than antiTNF agents,
treatment with >3
anti-TNF
therapies, active
inflammatory
disease other than
PsA, history of
ongoing infection
Previous use of
biologic agents
other than antiTNF agents;
active
inflammatory
disease other than
PsA, active
infection 2 weeks
prior, history of
chronic/ recurrent
infections
Previous therapy
with biologics
other than antiTNF agents,
treatment with >
3 anti-TNF
agents, presence
of active
inflammatory
disease other than
PsA, active
infection in the 2
weeks prior,
chronic/ recurrent
infections

Interventions

130

secukinumab 10
mg/kg
intravenously at
baseline, and at
weeks 2 and 4,
followed by 150
mg or 75 mg
subcutaneously
every 4 weeks
from week 8-24

72

Subcutaneous
secukinumab
(300,150, or 75
mg) at baseline,
weeks 1,2,3 and
4 and every 4
weeks thereafter

91

Intravenous
secukinumab 10
mg/kg at
baseline, weeks
2 and 4,
followed by
subcutaneous
150 or 75 mg
every 4 weeks
from week 8
until week 24
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OUTCOMES MEASURED
The studies measured patient oriented outcomes using the Health Assessment
Questionnaire Disability Index (HAQ-DI), a 20 item questionnaire that measures improvement in
physical function in the past week. The questionnaire includes questions regarding ability to
walk, eat, dress, groom oneself, take care of personal hygiene, arise from seated position and
other common daily activities. Scores for each item range from 0 (no difficulty) to 3 (unable to
do). The questions are grouped into 8 different categories and the average of the categories is
used to calculate the final score.
RESULTS
All three randomized control trials included patients 18 years or older with active PsA
which was classified as three or more swollen joints despite previous treatment with NSAIDs,
DMARDs and/or anti-TNF agents.7,8,9 Kavanaugh et al., and McInnes et al., allowed the use of
oral glucocorticoids and methotrexate as long as certain dosages were not exceded.7,8 All three
studies excluded patients who had previous therapy with biologics other than anti-TNF agents,
treatment with greater than three anti-TNF agents, presence of active inflammatory disease other
than PsA, a history of recurrent or chronic infection and patients under the age of 18.7,8,9
McInnes et al. also excluded those patients with a history of malignant disease in the past 5
years.8
In McInnes et al., a double blind, placebo controlled trial, patients were randomly
assigned to one of three treatment groups receiving 300, 150 or 75 mg of subcutaneous
secukinumab or a placebo group at baseline, weeks 1, 2, 3, 4 and every 4 weeks afterwards.8
Patients receiving placebo were re-assigned to receive one of the treatment doses (300,150, or 75
mg) every 4 weeks at week 16 depending on their responses.8 Non-responders were switched at
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week 16 while responders, or those who had >20% improvement from baseline in tender and
swollen joint count were switched at week 24.8 In this review, the 150 mg and 75 mg group
results will be focused on in order to maintain consistency with the methods of the other articles.
The mean change from baseline in HAQ-DI scores improved significantly in the 150 mg group
vs. placebo at week 24. The mean change from baseline of the HAQ-DI scores were sustained
throughout week 104 as compared to the first part of the study which ended at week 24 (see
Table 2). These statistics included missing values that were imputed as non-responses.8 At week
24, the p value for the group receiving 150 mg was 0.0555 and the p value for the 75 mg group
was 0.9195.8 No p values were recorded at week 104 due to the absence of a placebo group at
that time. Out of 397 patients, 76% receiving 150 mg and 66% receiving 75 mg completed the
full 104 weeks.8 At week 104, out of the 299 patients that were randomized to receive one of the
secukinumab doses, 24 discontinued in the 150 mg group and 34 discontinued in the 75 mg
group.8 The most common cause of discontinuation was lack of efficacy8 (Table 3) .
Table 2. Mean change from baseline in HAQ-DI at Weeks 24 and 104 in McInnes et al.

Mean change
from baseline
(SD) at week
24
Mean change
from baseline
(SD) at week
104

secukinumab 150 mg
(n=100)

secukinumab 75 mg
(n=99)

Placebo (n=98)

-0.48 (0.05)

-0.32 (0.05)

-0.31

-0.5

-0.3

N/A
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Table. 3 Patient compliance at week 104 in McInnes et al.
Discontinued
due to:
secukinumab
150 mg
(N=100)
secukinumab
75 mg
(N=99)
Placebo
groups
(N=98)

Adverse Lack of Physician Subject/
Effects efficacy Decision guardian
decision
6
7
2
9

Lost to
follow up

NonTotal
compliance

0

0

24

5

17

1

9

2

0

34

2

7

1

2

0

0

12

In Strand et al.’s study, there were two groups receiving secukinumab who both received
a 10 mg/kg intravenous dose of the drug at weeks 2 and 4, followed by either 150 mg or 75 mg
subcutaneous doses of secukinumab every 4 weeks after week 8.9 After week 16, the placebo
non-responders were reassigned to receive treatment and all subjects were re-randomized at
week 24 to either the group receiving 150 mg or 75 mg.9 In the groups receiving 150 mg and 75
mg, 41.1% and 39.6% were responders respectively versus 12.4% of subjects receiving placebo.9
The baseline mean HAQ-DI score and mean change from baseline are illustrated in Table 4. The
p value for both experimental groups at week 24 was <0.0001.9 The HAQ-DI scores improved at
week 52, however there was a lack of placebo group to compare to since those patients had been
re-randomized, therefore no p value was calculated.9 At week 24, 83 out of 202 patients were
receiving 150 mg of secukinumab, 80 out of 202 were receiving 75 mg of secukinumab and 25
out of 202 were receiving placebo.9
Table 4. Baseline HAQ-DI and mean change from baseline in HAQ-DI at week 24 and 52 in
Strand et al.
secukinumab 150
secukinumab 75 mg Placebo
mg (n=202)
(n=202)
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Baseline HAQDI
1.2 (0.7)
(SD)
Mean change from
-0.40 (0.04)
baseline (SD) at week
24
Mean change from
-0.46 (0.51)
baseline (SD) at week
52

1.3 (0.7)

1.2 (0.6)

-0.41 (0.04)

-0.17 (0.05)

-0.45 (0.61)

N/A

In the third study by Kavanaugh et al., patients who met the classification criteria were
randomized into one of 3 groups. One of which received a loading dose of 10 mg/kg of
intravenous secukinumab at week 2 and 4, followed by 150 mg subcutaneous secukinumab every
4 weeks after week 8.7 The second group received the same 10 mg IV loading dose at week 2
and 4 followed by a subcutaneous dose of 75 mg every 4 weeks after week 8.7 The third group
was the placebo group, following the same intravenous and subcutaneous administration
schedule.7 Non-responders were re-randomized at week 16 while responders at week 24.7 Out of
606 patients enrolled originally, 476 (78.5%) completed the 104 weeks.7 Lack of efficacy was
the main cause of discontinuation before week 104.7 The baseline HAQ-DI score along with the
mean change from baseline in those scores at weeks 24 and 104 are illustrated in Table 5. A p
value of <0.001 was calculated for both treatment groups in comparison with placebo at week
24.7 No p value was recorded at week 104 due to lack of a placebo group after the rerandomization.
Table 5. Baseline HAQ-DI and mean change from baseline in HAQ-DI at weeks 24 and 104 in
Kavanaugh et al.
secukinumab 150 mg secukinumab 75 mg
Placebo
(n=202)
(n=202)
Baseline HAQDI
1.2 (0.7)
1.3 (0.7)
1.2 (0.6)
(SD)
Mean change from
-0.40 (0.04)
-0.41 (0.04)
-0.17 (0.05)
baseline (SD) at week
24
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Mean change from
-0.42(0.55)
baseline (SD) at week
104

-0.41 (0.59)

N/A

DISCUSSION
There is currently no cure for psoriatic arthritis. Therefore, treatment is aimed at relieving
pain, preventing joint damage and increasing patients’ every day function.1 Biologics including
secukinumab are usually a last line effort for patients who cannot control their symptoms with
other medications.1 These three studies demonstrated the effectiveness of secukinumab in
improving physical function of patients with PsA. Not only were the treatment groups initially
better than placebo at improving patients’ physical function, those results were sustained
throughout later weeks of all three studies. The sample sizes were adequate and no new safety
concerns arose with extended length of treatment. Even though P values were not calculated at
the end of these studies due to ethical issues with continuation of placebo, Strand et al., and
Kavanaugh et al., had statistically significant p values at week 24.
Secukinumab was FDA approved in 2015 for the treatment of plaque psoriasis,
ankylosing spondylitis and psoriatic arthritis.10 It currently has no black box warnings and the
only contraindication is anyone with a history of a previous hypersensitivity reaction to
secukinumab.10 Precautions include infections, hypersensitivity reactions, inflammatory bowel
disease and tuberculosis.10 Live vaccines should not be given with secukinumab, however other
drug interactions have not been researched in trial studies.10
Limitations of these studies on secukinumab include a lack of long-term comparator. All
three studies re-randomized their placebo groups to receive treatment after a certain number of
weeks depending on patient responses. Even though HAQ-DI scores remained the same or
improved with longer duration of therapy, there was no placebo group to compare those scores
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to. However, it would be unethical to keep patients on a placebo treatment for an extended period
of time with no improvement. Strand et al., conducted a shorter study, measuring effects up to
week 52, while the other two studies continued monitoring patients up to week 104.7,8,9 A longer
research period is needed to successfully compare to the other studies as well as evaluate for long
term efficacy and side effects. Another limitation is that the concomitant use of methotrexate and
oral glucocorticoids in two of the studies7,8 could have skewed the results. Imputation of data in
McInnes et al., and Kavanaugh et al. did decrease the chance of bias due to discontinuations in
the placebo groups, however a “worst case” analysis was not done on all subjects that were lost
to follow-up.
CONCLUSIONS
Based upon this review of the three clinical trial studies, secukinumab is effective in
lowering HAQ-DI scores, therefore improving physical function in adult patients with active
psoriatic arthritis. In all three studies, mean change from baseline of HAQ-DI scores at week 24
demonstrated improvement in physical function in the two treatment groups in comparison to the
placebo groups.7,8,9 These improvements were sustained throughout further weeks of the
studies.7,8,9 This proves that secukinumab is efficacious in improving physical function in a
patients with psoriatic arthritis. A phase III future 5 study, a follow up of the Kavanaugh et al.
study has already been conducted which also shows improvement in HAQ-DI scores as well as
overall improvement in PsA symptoms with the use of secukinumab.11
For future studies, secukinumab should be compared to other biologics to evaluate if
improvements in physical function vary depending on which part of the immune system is
targeted. Secukinumab should be compared to other IL-17 inhibitors as well as biologics with
different targets cells. Specifically, TNF inhibitors should be researched because prior use was
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not excluded in all three studies. Different dosages of secukinumab could also be compared
considering the results of the 150 mg and 75 mg groups were fairly similar despite one dose
being twice as large. Although it is a fairly new biologic medication, secukinumab is already
demonstrating improvement in physical function in patients with psoriatic arthritis.
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